An interventional study of High Intensity Interval Training (HIIT) in Hodgkin Lymphoma, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 10 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by St. Jude Children's Research Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital — 6 open to participants now, 13 under way, none of them phase 3. Hodgkin Disease · St. Jude Children's Research Hospital.
Among the 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital, this one is the 13th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2026, is one of 4 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 25th registered.
1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.
Browse Hodgkin Disease studies →6 of the 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital are open now, in 1 country. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
St. Jude Children's Research Hospital · Sites in United States
Ages 18+ · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages 8+
St. Jude Children's Research Hospital · Sites in United States
St. Jude Children's Research Hospital · Sites in United States
Ages 12–24
By country, each count listing its studies:
Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 10 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 71 across the 18 interventional studies, 100 across the 9 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
3 of the studies in Hodgkin Disease by St. Jude Children's Research Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06421987St. Jude Children's Research HospitalCardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors | 2026-12 |
| NCT03755804St. Jude Children's Research HospitalPediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | 2027-01-01 |
| NCT00840047St. Jude Children's Research HospitalMethionine PET/CT Studies In Patients With Cancer | 2027-07-27 |
Add all 3 to your calendar (.ics) → With an account.
Among the 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Preliminary efficacy of the HIIT intervention for improved cardiorespiratory fitness, body composition, physical function, autonomic response to exercise, peripheral neuropathy, biological aging markers, and physical activity will also be evaluated.
Primary Objective:
To determine the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment.
Feasibility will be assessed by:
Hodgkin lymphoma survivors face elevated risks of cardiovascular disease and premature aging. HIIT, which alternates high-intensity effort with recovery periods, has shown benefits in adult cancer survivors but has not been tested in younger populations. This study will assess whether recently treated survivors can complete a remotely supervised 12-week HIIT program and evaluate its effects on multiple health outcomes. Participants will undergo baseline and post-intervention assessments including exercise testing, body composition, autonomic function, and blood biomarkers. The intervention is delivered via a secure web-based platform with live supervision by exercise physiologists.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will complete a 12-week HIIT program with three 25-minute sessions per week. Each session includes warm-up, five cycles of high-intensity intervals (80-95% peak HR) and recovery periods (50-60% peak HR), and cool-down.
Behavioral: High Intensity Interval Training (HIIT)
Participants will complete a 12-week HIIT program with three 25-minute sessions per week. Each session includes warm-up, five cycles of high-intensity intervals (80-95% peak HR) and recovery periods (50-60% peak HR), and cool-down.
Participation rate (percent of eligible participants approached who enroll)
Descriptive statistics will be reported
Time frame: Trial completion (12 weeks)
Completion rate (percentage of scheduled HIIT sessions attended and percentage of post-intervention testing sessions completed)
Descriptive statistics will be reported
Time frame: Trial completion (12 weeks)
Cardiorespiratory fitness (VO2peak, ml/kg/min)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Time frame: baseline at study entry, 12 weeks
Ewing battery score of autonomic function (0 to 5 points)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Time frame: baseline at study entry, 12 weeks
Body mass index (weight and height will be combined to report body mass index in kg/m2)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Time frame: baseline at study entry, 12 weeks
Percent body fat (%)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Time frame: baseline at study entry, 12 weeks
Lean mass percentage (%)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Time frame: baseline at study entry, 12 weeks
Visceral fat level (score)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Time frame: baseline at study entry, 12 weeks
Hand grip strength (kg)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Time frame: baseline at study entry, 12 weeks
Knee extension strength (N/kg)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Time frame: baseline at study entry, 12 weeks
Modified total neuropathy scale (0 to 24 points)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Time frame: baseline at study entry, 12 weeks
DNA methylation
Descriptive statistics of the change between baseline and 12 weeks will be reported
Time frame: baseline at study entry, 12 weeks
Mitochondrial DNA copy number
Descriptive statistics of the change between baseline and 12 weeks will be reported
Time frame: baseline at study entry, 12 weeks
Telomere length (kb)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Time frame: baseline at study entry, 12 weeks
High-sensitivity C-reactive protein (mg/L)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Time frame: baseline at study entry, 12 weeks
Interleukin-6 (pg/mL)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Time frame: baseline at study entry, 12 weeks
Physical activity (kilocalories per week)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Time frame: baseline at study entry, 12 weeks
Started Jun 2026 (actual). Primary completion is estimated for Jan 2028, 19 months after the start.
Of 50 non-industry interventional studies with no phase under Hodgkin Disease, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 128. This study's planned 19 months is below that.
Counting every sponsor, half of 53 studies reached it within 42 months; a quarter within 29 and three quarters within 128.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Jude Children's Research Hospital →